These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27245505)

  • 1. Does central sensitization help explain idiopathic overactive bladder?
    Reynolds WS; Dmochowski R; Wein A; Bruehl S
    Nat Rev Urol; 2016 Aug; 13(8):481-91. PubMed ID: 27245505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic syndromes and chronic pain in women with overactive bladder.
    Reynolds WS; Mock S; Zhang X; Kaufman M; Wein A; Bruehl S; Dmochowski R
    Neurourol Urodyn; 2017 Apr; 36(4):1113-1118. PubMed ID: 27367486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal summation to thermal stimuli is elevated in women with overactive bladder syndrome.
    Reynolds WS; Brown ET; Danford J; Kaufman M; Wein A; Dmochowski R; Bruehl S
    Neurourol Urodyn; 2017 Apr; 36(4):1108-1112. PubMed ID: 27434229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.
    Peyronnet B; Mironska E; Chapple C; Cardozo L; Oelke M; Dmochowski R; Amarenco G; Gamé X; Kirby R; Van Der Aa F; Cornu JN
    Eur Urol; 2019 Jun; 75(6):988-1000. PubMed ID: 30922690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Black box in overactive bladder: Central sensitization and its relationship with urinary symptom severity and quality of life.
    Celenay ST; Altay H; Bulbul SB; Oskay K
    Neurourol Urodyn; 2024 Mar; 43(3):620-627. PubMed ID: 38221860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous administration of mirabegron has advantages in inhibition of central sensitization compared with short-term treatment cessation in a mouse model of overactive bladder.
    Kwon J; Lee EJ; Park HR; Cho HJ; Jang JA; Yang H; An J; Park D; Kim YJ; Hur KJ; Kim JS; Yoshimura N
    Neurourol Urodyn; 2022 Aug; 41(6):1355-1363. PubMed ID: 35556260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder.
    Latini JM; Giannantoni A
    Expert Opin Pharmacother; 2011 May; 12(7):1017-27. PubMed ID: 21473706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology of refractory overactive bladder.
    Chen LC; Kuo HC
    Low Urin Tract Symptoms; 2019 Sep; 11(4):177-181. PubMed ID: 30900373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biopsychosocial impacts of anxiety on overactive bladder in women.
    Reynolds WS; McKernan LC; Dmochowski RR; Bruehl S
    Neurourol Urodyn; 2023 Apr; 42(4):778-784. PubMed ID: 36780135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric overactive bladder syndrome: pathophysiology and management.
    Franco I
    Paediatr Drugs; 2007; 9(6):379-90. PubMed ID: 18052408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The placebo effect in overactive bladder syndrome.
    Mangera A; Chapple CR; Kopp ZS; Plested M
    Nat Rev Urol; 2011 Jul; 8(9):495-503. PubMed ID: 21727941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urgency assessment in the evaluation of overactive bladder (OAB).
    Starkman JS; Dmochowski RR
    Neurourol Urodyn; 2008; 27(1):13-21. PubMed ID: 17671973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic overlap in overactive bladder and interstitial cystitis/bladder pain syndrome: development of a new algorithm.
    Ackerman AL; Lai HH; Parameshwar PS; Eilber KS; Anger JT
    BJU Int; 2019 Apr; 123(4):682-693. PubMed ID: 30253040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary Biomarkers in Overactive Bladder: Revisiting the Evidence in 2019.
    Antunes-Lopes T; Cruz F
    Eur Urol Focus; 2019 May; 5(3):329-336. PubMed ID: 31231010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment and diagnosis of overactive bladder in women.
    Rantell A
    Nurs Stand; 2013 Aug 28-Sep 3; 27(52):35-40. PubMed ID: 23980988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the pharmacologic management of overactive bladder: the present and the future.
    Ellsworth P; Kirshenbaum E
    Urol Nurs; 2010; 30(1):29-38, 53. PubMed ID: 20359143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of idiopathic overactive bladder and the success of treatment: a systematic review from ICI-RS 2013.
    Hanna-Mitchell AT; Kashyap M; Chan WV; Andersson KE; Tannenbaum C
    Neurourol Urodyn; 2014 Jun; 33(5):611-7. PubMed ID: 24844598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of urodynamic evaluation on the treatment of women with idiopathic overactive bladder: a systematic review.
    Serati M; Iacovelli V; Cantaluppi S; Braga A; Balzarro M; Pletto S; Soligo M; Finazzi Agrò E
    Minerva Urol Nefrol; 2020 Aug; 72(4):420-426. PubMed ID: 32026667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.
    Haab F
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S2-5. PubMed ID: 25042138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathophysiology of overactive bladder].
    Juszczak K; Wyczółkowski M; Thor PJ
    Przegl Lek; 2010; 67(7):488-90. PubMed ID: 21387762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.